尼古丁胺胺单核酸通过抑制喘中的SIRT3 SUMOylation来减轻呼吸道上皮质屏障功能障碍
Jiayuan Liang1, Chi Zhou1, Changyun Zhang1
1Department of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
尼古丁胺胺单核酸 (NMN) 可以通过改善呼吸道炎症和屏障功能来治疗过敏喘. 这通过抑制SIRT3 SUMOylation而发生,提供了潜在的新疗法策略.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 尼古丁胺胺氨基二核酸 (NAD+) 的下降与衰老和疾病有关.
- NAD+在喘相关的呼吸道上皮质屏障功能中的作用尚不清楚.
- 像尼古丁胺胺单核酸 (NMN) 这样的NAD+前体可能会带来治疗效益.
研究的目的:
- 为了研究NMN在治疗过敏性喘方面的疗效.
- 探索SIRT3在调解NMN效应中的作用.
- 阐明NMN在喘中的作用背后的分子机制.
主要方法:
- 室内灰尘虫 (HDM) 诱导的喘小鼠模型.
- 在体外和体内评估呼吸道上皮质屏障功能.
- 对SIRT3 SUMOylation,降解和与SENP1.1相互作用的分析.
- 对SIRT3及其SUMOylation位点进行基因操纵.
主要成果:
- 在喘小鼠中,NMN缓解了呼吸道炎症和粘液产生.
- 在HDM诱导的喘中,NMN减轻了呼吸道上皮质屏障的破坏.
- 抑制SIRT3消除了NMN的治疗作用.
- HDM诱导SIRT3 SUMOylation和降解,而NMN可以逆转这种情况.
- SENP1从SIRT3中解SUMO;NMN逆转了HDM诱导的SENP1下调.
结论:
- 在喘中,NMN治疗减轻了呼吸道上皮质屏障功能障碍.
- 该机制涉及NMN抑制SIRT3 SUMOylation和随后的降解.
- 向SIRT3 SUMOylation为过敏性喘提供了一个潜在的治疗策略.
更多相关视频
06:12Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
09:07Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research
Published on: July 12, 2024
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
